SRR934804
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.626
- G2M_CHECKPOINT+0.619
- MYC_TARGETS_V1+0.482
- MITOTIC_SPINDLE+0.476
- MTORC1_SIGNALING+0.456
- MYC_TARGETS_V2+0.450
- PROTEIN_SECRETION+0.384
- UNFOLDED_PROTEIN_RESPONSE+0.372
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.313
- DNA_REPAIR+0.312
Top 10 suppressed
- KRAS_SIGNALING_DN-0.409
- PANCREAS_BETA_CELLS-0.224
- MYOGENESIS-0.218
- APICAL_SURFACE-0.199
- BILE_ACID_METABOLISM-0.186
- OXIDATIVE_PHOSPHORYLATION-0.171
- WNT_BETA_CATENIN_SIGNALING-0.155
- NOTCH_SIGNALING-0.143
- HEDGEHOG_SIGNALING-0.093
- FATTY_ACID_METABOLISM-0.086
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934852 | — | — | 0.899 |
| 2 | SRR934851 | — | — | 0.887 |
| 3 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.886 |
| 4 | SRR934935 | — | — | 0.884 |
| 5 | SRR934835 | — | — | 0.880 |
| 6 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.880 |
| 7 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.876 |
| 8 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.873 |
| 9 | SRR934925 | — | — | 0.872 |
| 10 | SRR934981 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.626 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.619 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.482 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.476 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.456 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.384 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.372 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.313 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.312 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.266 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.254 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.229 | Inavolisib | — uncovered |
| COMPLEMENT | 0.226 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.223 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.209 | Inavolisib | — uncovered |
| APOPTOSIS | 0.208 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.205 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.203 | Inavolisib | — uncovered |